Real innovation in healthcare has always been a challenge. And with the rise of value-based healthcare, the stakes have never been higher. Patients, Payers, and Providers are all seeking solutions that deliver real clinical and economic value. Boston Healthcare is a global strategy consulting firm that advises clients on how to Optimize Innovation Value in a complex clinical and economic environment. We help clients unlock the value of medical devices, diagnostics, and biopharmaceuticals that have the potential to transform patient care and significantly improve health outcomes.
BHA’s multi-disciplinary, global teams bring deep industry and functional expertise and a range of perspectives to initiate change through leading-edge insights and advisory. We work in a uniquely collaborative model across the firm and throughout all levels of an organization to deliver results that help our clients grow and achieve.
Who We Are
Boston Healthcare works with clients to solve some of the most challenging business problems facing healthcare innovators. We draw on the diverse thinking and creativity of our team every day to deliver insights that help leaders make critical business decisions. And the foundation of what we do is the true partnership with our clients, knowing that together we can deliver innovation that makes a difference.
The drive for value in healthcare creates extraordinary opportunity for creativity and innovation. BHA helps innovators create, navigate, grow, and achieve. We excel in capturing value for healthcare technologies and services that make a difference, and believe in the power of innovation and organizations to improve patients’ lives.
Manufacturers face new barriers to enter the European markets, such as evidentiary requirements for demonstrating comparative efficacy and cost-effectiveness, complex price negotiations, and innovative access agreements.
Our presence in the Asia-Pacific region enables us to continue to effectively provide our global clients with strong support for meeting the continually evolving evidence and market access requirements from these emerging markets.